Adults with blood cancer that are unable to participate in the PRESERVE I clinical study may be eligible to participate in the HOPE Program. The patient’s doctor must determine that they are eligible for an allogeneic bone marrow transplant and that the potential benefits outweigh the potential risks. The determination on program eligibility is made by Ossium’s clinical staff based on information provided by the patient and their doctor.*

Latest News

Join Our Team

At Ossium, we’re always looking for talented, mission-driven people.